Overview

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

Status:
Completed
Trial end date:
2024-01-02
Target enrollment:
Participant gender:
Summary
A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.
Phase:
Phase 1
Details
Lead Sponsor:
Tempero Bio, Inc.
Collaborator:
National Institute on Drug Abuse (NIDA)